ArticleDrug delivery and translational research2026
Antimicrobial and regenerative copper-doped hybrid biomaterials for bone infection treatment.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bone tissue is endowed with intrinsic regenerative capacity. This is compromised in cases of major alterations like in trauma, surgical removal of cancer lesions, and infections. Osteomyelitis (OM) is an infectious disease of the bone primarily caused by the gram-positive bacterium Staphylococcus aureus and characterized by extensive tissue remodelling and inflammation. Local and systemic antimicrobial treatments are the standard of care; however their efficacy is often limited by immune-mediated vascular damage and biofilm formation. Antimicrobial-loaded biomaterials offer a promising alternative. In this regard, hybrid scaffolds made of hydroxyapatite nanocrystals grown on collagen fibers and mimetic of bone extracellular matrix has already demonstrated to support cell functions and resorb over time. Also, they can be doped with bioactive and antimicrobial ions and release them in a controlled and sustained manner during scaffold degradation and tissue regeneration. In this study, we incorporated Cu²⁺-doped hydroxyapatite into collagen scaffolds (Col/CuHA) with the aim of developing a biomaterial capable at a time to prevent/treat bone infections and promote tissue regeneration. These matrices recapitulated the architecture of bone tissue and released Cu²⁺ ions with bactericidal activity towards a biofilm-forming isolate of Staphylococcus aureus. In vitro experiments in conditions mimicking dynamic fluid exchanges allowed identification of optimal Cu²⁺ loads with balanced antimicrobial activity and cytocompatibility. In vivo preliminary observations from a murine model of ectopic scaffold implantation suggested that these biomaterials can be integrated in the host tissue, thus further corroborating their biocompatibility with the applied loads of Cu
Identifiers
42162538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.